Keywords: پلی سیتمیورا; Erythrocytosis; essential thrombocythaemia; JAK inhibitors; myelofibrosis; myeloproliferative; thrombocytosis; polycythaemia vera;
مقالات ISI پلی سیتمیورا (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: پلی سیتمیورا; Myelodysplastic syndromes; Acute myeloid leukaemia; Myeloproliferative neoplasms; Polycythaemia vera; Essential thrombocythaemia;
Keywords: پلی سیتمیورا; Carcinoma epidermoide de esófago; Adenocarcinoma de colon; Policitemia vera; Neoplasias primitivas múltiples; DiagnósticoOesophageal squamous cell carcinoma; Colon adenocarcinoma; Polycythaemia vera; Multiple primary primitive malignancies; Diagnosis
ReviewAfter 10Â years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera
Keywords: پلی سیتمیورا; Polycythaemia vera; Erythrocytosis; Myeloproliferative; JAK2;
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells
Keywords: پلی سیتمیورا; AEBSF; 4-(2-aminoethyl)-benzolsulfonylfluorid; DMEM; Dulbecco's modified Eagle's medium; EGFR; epidermal growth factor receptor; Epo; erythropoietin; EpoR; erythropoietin receptor; Erk; extracellular signal regulated kinase; FCS; fetal calf serum; Gab1; G
An update on BCR-ABL1-negative myeloproliferative neoplasms
Keywords: پلی سیتمیورا; chronic eosinophilic leukaemia; chronic neutrophilic leukaemia; essential thrombocythaemia; myeloproliferative neoplasm; polycythaemia vera; primary myelofibrosisMPN, myeloproliferative neoplasm; MPN, U, myeloproliferative neoplasm, unclassifiable; MDS, m
Myeloproliferative neoplasms
Keywords: پلی سیتمیورا; erythrocytosis; essential thrombocythaemia; JAK inhibitors; myelofibrosis; myeloproliferative; polycythaemia vera; thrombocytosis
Regular ArticleInferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease
Keywords: پلی سیتمیورا; CMD; chronic myeloproliferative disease; ET; essential thrombocythaemia; IVC; inferior vena cava; IVCT; inferior vena cava thrombosis; LE-DVT; lower extremity deep vein thrombosis; PV; polycythaemia vera; RT-PCR; real-time polymerase chain reaction; SVT;
Mechanisms of mutations in myeloproliferative neoplasms
Keywords: پلی سیتمیورا; myeloproliferative neoplasms; MPN; essential thrombocytosis; myelofibrosis; polycythaemia vera; JAK2; TET2; MPL; mutations
Diagnosis of chronic myeloproliferative neoplasms with special emphasis on early stages
Keywords: پلی سیتمیورا; bone marrow features; chronic myeloproliferative neoplasms; essential thrombocythaemia; JAK2 V617F mutation; myelofibrotic transformation; myeloid metaplasia; polycythaemia vera; primary myelofibrosis; prodromal stages; prognosis
Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence
Keywords: پلی سیتمیورا; Myeloproliferative diseases; Jak2; Tyk2; Polycythaemia vera; Essential thrombocythaemia
Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?
Keywords: پلی سیتمیورا; Statins; Polycythaemia vera; Antiproliferative; Proapoptotic; Antithrombotic